Last reviewed · How we verify
Echinaforce junior
Echinaforce junior is a herbal preparation derived from Echinacea purpurea that stimulates immune function to help prevent and reduce the severity of upper respiratory tract infections.
Echinaforce junior is a herbal preparation derived from Echinacea purpurea that stimulates immune function to help prevent and reduce the severity of upper respiratory tract infections. Used for Prevention and treatment of upper respiratory tract infections in children, Common cold symptom reduction in pediatric populations.
At a glance
| Generic name | Echinaforce junior |
|---|---|
| Sponsor | A. Vogel AG |
| Drug class | Herbal immune stimulant |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The preparation contains active compounds from Echinacea purpurea (aerial parts and roots) that are believed to enhance innate immune responses by activating macrophages, natural killer cells, and other immune cells. This immune stimulation may reduce infection duration and symptom severity, particularly for common colds and upper respiratory infections in children.
Approved indications
- Prevention and treatment of upper respiratory tract infections in children
- Common cold symptom reduction in pediatric populations
Common side effects
- Gastrointestinal upset
- Allergic reactions (rare, in echinacea-sensitive individuals)
- Rash
Key clinical trials
- Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections (PHASE4)
- Study of Echinaforce Junior Tablets in Children With Acute Colds
- Echinacea Junior vs Vitamin C in Children 4-12 Years Old (PHASE3)
- Echinaforce Junior Bioavailability Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |